Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in chronic-active antibody-mediated kidney transplant rejection
NCT03737136Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2019
- Primary completion
- May 2024
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Randomised trial of bortezomib in antibody mediated rejection (AMR) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Transplanted kidney survival at 6 months. Started Nov 2019; status: completed.
02
Drugs
bortezomib
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03737136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737136.